$OMER

Cancelmo Peter B sold $930K of OMER

Cancelmo Peter B (VP, General Counsel) sold 50,000 shares of OMEROS CORP (OMER) at an average of $18.59 ($18.54–$18.65, $0.93M total) across 2 trades over 2026-08-28 to 2026-08-31.

Original reporting
SEC EDGAR · Cancelmo Peter B
Published Sep 1, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 10:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Bearish
medium confidence
Mentioned
$OMER
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERBearishLow
01

Why it matters

The sale reduces insider ownership, which some investors view as a negative signal, though the amount is modest relative to market cap.

02

Market read

A routine insider sale with limited market impact.

03

What to watch

No 10b5-1 plan; the insider may have personal liquidity needs.

Relevance 5/10Novelty 4/10Timing: filed post-market on Sep 1, 2026

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$OMERBearishMedium confidence
Context

VP and General Counsel Peter B. Cancelmo sold 50,000 shares for $929,667, reducing his stake to 200 shares.

Expected impact

Possible modest downward pressure in the near term.

Evidence & confidence

Large insider sell of ~0.5% of float, but no accompanying buyback or other catalyst.

Market effects

Minimal impact on the broader biotech sector.

Limited to US markets where OMER trades.

Low

Counterpoint

The sale could be unrelated to confidence, perhaps a tax or diversification move.

Key entities

  • Peter B. Cancelmo

    Vice President, General Counsel of OMEROS CORP

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

$OMERHighAI 8/10

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.